The gestational diabetes market was valued at USD 3.39 Billion in 2025 and is expected to grow at a CAGR of 8.40%, reaching USD 7.59 Billion by 2035. The market growth is driven by increasing awareness of maternal health and the adoption of advanced diagnostic tools for early detection of gestational diabetes. Rising investments in digital health solutions, such as continuous glucose monitoring and telemedicine, are enhancing patient management. Expanding prenatal care programs and the growing prevalence of diabetes globally are expected to further support market growth in the forecast period.
Base Year
Historical Period
Forecast Period
In April 2024, new research from Western Sydney University shows early gestational diabetes diagnosis and treatment reduce birth complications and healthcare costs by up to 10%, supporting market growth through increased adoption of early screening and intervention strategies.
One of the key market trends is the adoption of pregnancy-specific ‘artificial pancreas’ systems. For instance, in September 2025, NHS England rolled out advanced hybrid closed-loop technology to help pregnant women with type 1 diabetes manage blood glucose effectively.
The market is experiencing steady growth due to rising prevalence, increasing awareness, and technological advancements. Strategic initiatives and product innovations by key players are further accelerating market expansion and competitive dynamics.
Compound Annual Growth Rate
8.4%
Value in USD Billion
2026-2035
*this image is indicative*
Gestational diabetes poses significant health challenges for expectant mothers, affecting both maternal and fetal well-being. Rising awareness, routine prenatal screening, and advancements in glucose monitoring and management have strengthened early diagnosis and treatment. The market is expanding due to increasing prevalence, innovative therapeutics, and demand for improved maternal care. Key players are focusing on advanced monitoring devices, personalized treatment options, and strategic collaborations to enhance patient outcomes. The market is poised to reach USD 7.59 Billion by 2035, reflecting robust growth driven by healthcare investments and rising adoption of modern diabetes management solutions.
Rising Focus on Digital Gestational Diabetes Care to Boost the Market Growth
The increasing adoption of digital tools for gestational diabetes management is significantly driving growth in the global market. In March 2024, the Maternity Foundation, supported by the World Diabetes Foundation, launched new modules on antenatal care and gestational diabetes in the Indian version of the Safe Delivery App. These modules, based on national clinical guidelines, provide healthcare professionals with guidance on screening, diagnosis, and management of gestational diabetes. By enhancing timely detection and intervention, such initiatives improve maternal and neonatal outcomes, thereby supporting sustained growth in the market worldwide.
Some of the trends in the market include an increasing emphasis on early diagnosis and the growing adoption of reimbursed remote monitoring solutions.
Rising Focus on Early Detection to Enhance the Market Demand
There is a growing emphasis on early profiling to detect gestational diabetes, a condition that poses significant risks to maternal and fetal health. In July 2025, a study highlighted that specific gut microbiota signatures during the first trimester could predict gestational diabetes, enabling timely interventions and personalized care. This focus on early, non-invasive analysis is expected to improve pregnancy outcomes and reduce complications. Such advancements are driving innovation in diagnostics, positioning the gestational diabetes market for notable growth in the coming years.
Expansion of Remote Monitoring to Boost Gestational Diabetes Market Value
The adoption of digital health solutions for gestational diabetes (GDM) management is gaining momentum, driven by regulatory support and reimbursement policies. In January 2025, Glooko, Inc. secured reimbursement in France for its Glooko XT platform, enabling healthcare providers to remotely monitor non–insulin-treated GDM patients. This milestone highlights the increasing acceptance of telehealth in prenatal care, offering improved patient engagement and timely interventions. Such initiatives are expected to enhance access to personalized care and support better maternal and fetal outcomes, ultimately fueling growth in the market.
Oral Medications Segment to Hold Significant Share for Market by Route of Administration
The market includes various treatment options for managing the condition, segmented by route of administration into oral and parenteral forms. Oral medications offer convenience, ease of use, and better patient compliance, while parenteral options are typically reserved for more severe cases or when oral therapy is insufficient. Among these, oral administration is expected to lead the market due to its widespread adoption, cost-effectiveness, and suitability for long-term management, driving significant growth in the coming years.
The market is divided into regions such as the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these regions, the United States is expected to lead the market due to rising awareness, increased screening, and the growing prevalence of maternal obesity and lifestyle-related risk factors. According to Tanvi Nayak et al., 2024, of the 17,432,486 individuals with live births between 2019 and 2023, the overall prevalence of GDM per 100 live births increased from 6.9 in 2019 to 8.0 in 2023, with an average annual percent change of 3.2. Along with the rising prevalence, the United States continues to prioritize early diagnosis and management, supporting sustained market growth.
The key features of the market report comprise clinical trials analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Sanofi is a global biopharmaceutical company specializing in innovative healthcare solutions. In the gestational diabetes market, Sanofi offers Lantus® (Insulin Glargine Injection I.P.), a long-acting recombinant human insulin analogue designed for adults, adolescents, and children aged two years and above. Lantus® provides a peakless glucose-lowering effect, supporting stable blood sugar management, and demonstrates Sanofi’s active role in advancing diabetes care globally.
Eli Lilly and Company is a global pharmaceutical leader dedicated to improving diabetes care. Their comprehensive approach encompasses education, treatment, and innovative technologies. In the realm of gestational diabetes, Lilly offers educational resources to assist healthcare professionals and patients in understanding and managing the condition. Additionally, Lilly's Tempo™ Personalized Diabetes Management Platform provides tools to support diabetes self-management. While specific products for gestational diabetes are not detailed, Lilly's commitment to diabetes care underscores their involvement in this market segment.
Bayer AG is a global pharmaceutical and life sciences company committed to advancing health and nutrition. Its product, Acarbose (marketed as Glucobay and Precose), is an alpha-glucosidase inhibitor used to manage type 2 diabetes and prediabetes. Bayer has conducted clinical trials, such as the PREDIAP study, to evaluate Acarbose's efficacy in delaying the onset of type 2 diabetes in individuals with impaired glucose tolerance. Additionally, Acarbose has been investigated for its potential use in managing gestational diabetes mellitus (GDM), with studies exploring its safety and effectiveness compared to insulin therapy. These efforts underscore Bayer's active role in addressing diabetes care across various patient populations.
GlaxoSmithKline plc (GSK) is a global healthcare company focused on developing innovative medicines and therapies. In the context of gestational diabetes, GSK offers AVANDIA (rosiglitazone maleate tablets), an oral thiazolidinedione antidiabetic agent used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. GSK’s involvement in this market centers on providing pharmacological options to manage hyperglycemia, contributing to better maternal and fetal outcomes.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Merck & Co., Inc., Glenmark Pharmaceuticals, AstraZeneca plc, Pfizer Inc., and Biocon Limited.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Treatment Type
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Country
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share